Vivoryon Therapeutics N.V.

As of June 30, 2026, Vivoryon Therapeutics N.V. carries a market capitalization of 32.13M, placing it among publicly traded companies globally. Its enterprise value stands at 29.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vivoryon Therapeutics N.V. has 29.61M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Vivoryon Therapeutics N.V. maintains a current ratio of 4.56, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Vivoryon Therapeutics N.V.'s stock has declined approximately 45.02% over the past 52 weeks. The 50-day moving average sits at 1.08, while the 200-day moving average is 1.24.

As of June 30, 2026, Vivoryon Therapeutics N.V. holds 2.54M in cash and equivalents against 76,000.00 in total debt, resulting in a net debt position of -2.45M. Total book value stands at 1.57M, with working capital of 2.45M providing operational flexibility.

Vivoryon Therapeutics N.V.'s most recent stock split took place on October 10, 2019.